Boston Scientific BSX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net sales of reportable segments by Business | ||||||
| Cardiovascular | $3.5B+10.9% | $3.47B+16.4% | $3.33B+21.4% | $3.34B+25.4% | $3.16B+28.4% | |
| MedSurg | $1.7B+5.7% | $1.8B+10.1% | $1.71B+15.5% | $1.71B+14.6% | $1.61B+13.5% | |
| Net Sales by Business | ||||||
| Cardiovascular | $3.5B+13.5% | $3.48B+18.2% | $3.34B+22.4% | $3.35B+26.8% | $3.09B+26.2% | |
| MedSurg | $1.7B+7.9% | $1.81B+11.7% | $1.72B+16.4% | $1.72B+15.7% | $1.58B+11.7% | |
| Total assets of reportable segments by Business | ||||||
| Cardiovascular | $8.25B+11.3% | $8B+12.9% | $7.8B— | $7.5B— | $7.41B— | |
| MedSurg | $3.73B+19.2% | $3.39B+9.7% | $3.39B— | $3.33B— | $3.13B— | |
| Other segment items, percentage of net sale by Business | ||||||
| Cardiovascular | 0.2%0.0pp | —— | 0.2%0.0pp | 0.2%0.0pp | 0.2%0.0pp | |
| MedSurg | 0.3%0.0pp | —— | 0.3%— | 0.5%+0.2pp | 0.3%0.0pp | |
| Other segment items by Business | ||||||
| Cardiovascular | $7M+16.7% | $7M+40.0% | $6M+20.0% | $6M+20.0% | $6M+50.0% | |
| MedSurg | $5M-16.7% | $2M-60.0% | $5M— | $8M+100% | $6M+20.0% | |
| Segment operating income, percentage of net sale by Business | ||||||
| Cardiovascular | 32.1%-1.7pp | —— | 34.1%+2.6pp | 31.9%+2.5pp | 33.8%+6.4pp | |
| MedSurg | 31.3%-2.0pp | —— | 33%-1.9pp | 34.9%0.0pp | 33.3%-0.9pp | |
| Operating Income (Loss), Adjusted by Business | ||||||
| Cardiovascular | $1.13B+5.3% | $1.05B+15.1% | $1.14B+31.7% | $1.07B+36.2% | $1.07B+58.5% | |
| MedSurg | $533M-0.6% | $575M+2.1% | $566M+9.3% | $599M+14.8% | $536M+10.5% | |
| Selling, general and administrative expenses, percentage of net sale by Business | ||||||
| Cardiovascular | 27.4%-0.3pp | 0.3%— | 27.6%-1.3pp | 27.2%-2.7pp | 27.7%-2.4pp | |
| MedSurg | 32.8%+1.0pp | —— | 31%+1.3pp | 30.2%-0.2pp | 31.8%+0.8pp | |
| Cost of products sold by Business | ||||||
| Cardiovascular | $1.07B+15.2% | $1.04B+14.6% | $930M+11.0% | $1.05B+22.9% | $926M+14.2% | |
| MedSurg | $478M+9.9% | $529M+15.8% | $483M+17.2% | $470M+17.2% | $435M+14.2% | |
| Cost of products sold, percentage of net sale by Business | ||||||
| Cardiovascular | 30.5%+1.2pp | 0.1%— | 27.9%-2.7pp | 31.3%-0.6pp | 29.3%-3.7pp | |
| MedSurg | 28.1%+1.1pp | 0.5%+0.2pp | 28.2%+0.4pp | 27.4%+0.6pp | 27%+0.1pp | |
| Research and development expenses, percentage of net sale by Business | ||||||
| Cardiovascular | 9.8%+0.8pp | 0.4%+0.3pp | 10.1%+1.2pp | 9.4%+0.7pp | 9%-0.3pp | |
| MedSurg | 7.5%0.0pp | 0.1%0.0pp | 7.5%-0.1pp | 7%-0.6pp | 7.5%-0.1pp | |
| Selling, general and administrative expenses by Business | ||||||
| Cardiovascular | $959M+9.9% | $990M+13.3% | $920M+16.3% | $908M+14.1% | $873M+18.0% | |
| MedSurg | $557M+8.8% | $560M+15.9% | $531M+20.7% | $517M+13.9% | $512M+16.6% | |
| Impact of foreign currency fluctuations and purchase price and other adjustments by Business | ||||||
| Cardiovascular | -$14M-147% | $9M+111% | —— | $62M+875% | $30M+236% | |
| MedSurg | -$5M-129% | $9M+169% | $1M— | $26M+2,700% | $17M+159% | |
| Research and development expenses by Business | ||||||
| Cardiovascular | $343M+21.2% | $375M+35.9% | $337M+38.1% | $315M+36.4% | $283M+24.1% | |
| MedSurg | $127M+5.0% | $138M+7.8% | $128M+13.3% | $120M+5.3% | $121M+13.1% | |
| Goodwill by Business | ||||||
| Cardiovascular | $10.56B+7.3% | $10.57B+10.1% | $10.53B+8.7% | $10.55B+16.5% | $9.84B+9.1% | |
| MedSurg | $7.98B+6.4% | $7.71B+3.0% | $7.69B+43.7% | $7.53B+40.9% | $7.5B+40.4% | |
| Depreciation by Business | ||||||
| Cardiovascular | $89M+14.1% | $105M+15.4% | $89M+18.7% | $83M+16.9% | $78M+18.2% | |
| MedSurg | $29M+7.4% | $31M0.0% | $29M+7.4% | $28M+3.7% | $27M+12.5% | |
| Goodwill acquired by Business | ||||||
| Cardiovascular | $0-100% | $37M+517% | $0-100% | $648M+1,309% | $205M— | |
| MedSurg | $274M— | $14M-99.3% | $159M— | $0— | $0-100% | |
| Net Sales by Product | ||||||
| Cardiac Rhythm Management | $578M0.0% | $586M+3.5% | $578M+3.0% | $590M+2.4% | $578M+0.5% | |
| Electrophysiology | $905M+24.0% | $890M+37.1% | $865M+64.1% | $840M+96.3% | $730M+143% | |
| Endoscopy | $736M+9.4% | $759M+9.8% | $747M+10.2% | $737M+9.0% | $673M+4.8% | |
| Interventional Cardiology & Vascular Therapies | $1.24B+10.7% | —— | $686M+3.8% | $731M+9.9% | $1.12B+72.4% | |
| Interventional Oncology & Embolization | $268M+17.5% | —— | —— | —— | $228M+6.5% | |
| Neuromodulation | $318M+17.3% | $333M+11.4% | $293M+9.3% | $303M+7.4% | $271M+5.9% | |
| Urology | $646M+2.1% | $717M+13.8% | $682M+28.2% | $676M+28.8% | $633M+23.4% | |
| Watchman | $506M+19.1% | $535M+29.5% | $512M+34.7% | $486M+28.2% | $425M+23.5% | |
| Net Sales by Geography | ||||||
| Asia-Pacific | $803M+14.6% | $788M+15.2% | $802M+17.3% | $790M+17.9% | $701M+8.3% | |
| Europe, Middle East and Africa | $932M+10.2% | $933M+12.4% | $793M+2.6% | $878M+6.8% | $846M+5.4% | |
| Latin America and Canada | $185M+19.4% | $179M+15.5% | $175M+10.1% | $169M+4.3% | $155M+4.0% | |
| U.S. | $3.28B+10.9% | $3.39B+17.0% | $3.29B+27.0% | $3.22B+30.7% | $2.96B+31.1% | |
| Long-Lived Assets by Geography | ||||||
| Costa Rica | $640M+14.9% | $637M+20.2% | $593M— | $574M— | $557M— | |
| Ireland | $750M+14.5% | $750M+18.9% | $707M— | $701M— | $655M— | |
| U.S. | $1.95B+28.0% | $1.92B+31.3% | $1.81B— | $1.53B— | $1.52B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Boston Scientific break its business down?
- Boston Scientific (BSX) reports net sales of reportable segments by business across 2 parts — Cardiovascular and MedSurg. Each is extracted from the segment footnotes and tracked over time.
- Where does Boston Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Boston Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
